Rosuvastatin Reduces Ischemia-reperfusion Injury in Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2014 Aug 27

PMID 25156269

Citations 7

Authors

Fangyong Jiang

Jin Yang

Linchao Zhang

Rongshan Li

Liuan Zhuo

Liping Sun

Qin Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Statins reduce the incidence of cardiovascular events after percutaneous coronary intervention (PCI), but no clinical studies have investigated the role of statins in ischemia-reperfusion injury after PCI.

Hypothesis: Rosuvastatin could reduce ischemia-reperfusion injury in patients with acute coronary syndrome treated with PCI.

Objectives: We investigated the effects of rosuvastatin on ischemia-reperfusion injury in patients with acute coronary syndrome after PCI and evaluated short-term prognosis.

Methods: Patients scheduled for emergent PCI were given either rosuvastatin for ≥6 months (10 mg/d, every night; n = 55) or no statins (control group; n = 65). Serum superoxide dismutase activity, malondialdehyde, brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP) were determined before and after PCI, as well as left ventricular ejection fraction and left ventricular end-diastolic volume. Major adverse cardiac events were observed at follow-ups for 6 months.

Results: Superoxide dismutase activity in the rosuvastatin-treated group was higher than that of the control group; serum levels of malondialdehyde were lower. BNP and hs-CRP levels in the rosuvastatin-treated group were lower than that of the control group. Four weeks after PCI, the left ventricular ejection fraction in the treatment group was higher than that of the control group, and the left ventricular end-diastolic volume was lower. At the 6-month follow-up, there was no difference in major adverse cardiac events between the 2 groups.

Conclusions: Rosuvastatin before PCI reduced ischemia-reperfusion injury in patients with acute coronary syndrome, which suggests the importance of application of rosuvastatin before PCI for early intervention.

Citing Articles

Effect of Statins on Superoxide Dismutase Level: A Systematic Review.

Daliri M, Simental-Mendia L, Jamialahmadi T, Kesharwani P, Reiner Z, Sahebkar A Curr Med Chem. 2023; 32(5):1007-1016.

PMID: 37653630 DOI: 10.2174/0929867331666230831145809.

Research Progress on the Pharmacological Action of Schisantherin A.

Xiao Z, Xiao W, Li G Evid Based Complement Alternat Med. 2022; 2022:6420865.

PMID: 35190748 PMC: 8858060. DOI: 10.1155/2022/6420865.

Propofol Mediated Protection of the Brain From Ischemia/Reperfusion Injury Through the Regulation of Microglial Connexin 43.

Zhang T, Wang Y, Xia Q, Tu Z, Sun J, Jing Q Front Cell Dev Biol. 2021; 9:637233.

PMID: 34169070 PMC: 8217990. DOI: 10.3389/fcell.2021.637233.

Rosuvastatin protects isolated hearts against ischemia-reperfusion injury: role of Akt-GSK-3β, metabolic environment, and mitochondrial permeability transition pore.

Velez D, Mestre-Cordero V, Hermann R, Perego J, Harriet S, Fernandez-Pazos M J Physiol Biochem. 2020; 76(1):85-98.

PMID: 31916218 DOI: 10.1007/s13105-019-00718-z.

Baicalin Suppresses Hypoxia-Reoxygenation-Induced Arterial Endothelial Cell Apoptosis via Suppressing PKCδ/p53 Signaling.

Shou X, Wang B, Zhou R, Wang L, Ren A, Xin S Med Sci Monit. 2017; 23:6057-6063.

PMID: 29272263 PMC: 5747146. DOI: 10.12659/msm.907989.

References

Katsaros K, Kastl S, Zorn G, Maurer G, Wojta J, Huber K . Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv. 2010; 3(1):90-7. DOI: 10.1016/j.jcin.2009.10.023. View

Hirayama A, Kusuoka H, Yamamoto H, Sakata Y, Asakura M, Higuchi Y . Usefulness of plasma brain natriuretic peptide concentration for predicting subsequent left ventricular remodeling after coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2006; 98(4):453-7. DOI: 10.1016/j.amjcard.2006.03.022. View

Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E . Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007; 49(3):290-7. DOI: 10.1016/j.jacc.2006.08.054. View

Roman R, Camargo P, Borges F, Rossini A, Polanczyk C . Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis. 2010; 21(3):129-36. DOI: 10.1097/MCA.0b013e328333f50d. View

Miao L, St Clair D . Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009; 47(4):344-56. PMC: 2731574. DOI: 10.1016/j.freeradbiomed.2009.05.018. View

Uraizee A, Reimer K, Murry C, Jennings R . Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs. Circulation. 1987; 75(6):1237-48. DOI: 10.1161/01.cir.75.6.1237. View

Nissen S, Tuzcu E, Schoenhagen P, Crowe T, Sasiela W, Tsai J . Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352(1):29-38. DOI: 10.1056/NEJMoa042000. View

Herrmann J, Lennon R, Barsness G, Sandhu G, Gulati R, Best P . High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. Circ Cardiovasc Interv. 2012; 5(6):783-90. DOI: 10.1161/CIRCINTERVENTIONS.112.972182. View

Fujimoto H, Suzuki T, Aizawa K, Sawaki D, Ishida J, Ando J . Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin Chem. 2013; 59(9):1330-7. DOI: 10.1373/clinchem.2013.203406. View

10.

Biasillo G, Leo M, Della Bona R, Biasucci L . Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med. 2010; 5(3):225-33. DOI: 10.1007/s11739-010-0361-1. View

11.

Ozacmak V, Sayan H, Akyildiz Igdem A, Cetin A, Ozacmak I . Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. Eur J Pharmacol. 2007; 562(1-2):138-47. DOI: 10.1016/j.ejphar.2007.01.061. View

12.

Dhaliwal A, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J . Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009; 15(4):293-9. DOI: 10.1016/j.cardfail.2008.11.007. View

13.

Grabowski M, Filipiak K, Karpinski G, Wretowski D, Rdzanek A, Huczek Z . Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J. 2004; 148(4):655-62. DOI: 10.1016/j.ahj.2004.04.023. View

14.

Braunwald E, Antman E, Beasley J, Califf R, Cheitlin M, Hochman J . ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice.... J Am Coll Cardiol. 2002; 40(7):1366-74. DOI: 10.1016/s0735-1097(02)02336-7. View

15.

Turner J, Rakhmilevich A, Burdelya L, Neal Z, Imboden M, Sondel P . Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol. 2000; 166(1):89-94. DOI: 10.4049/jimmunol.166.1.89. View

16.

Frohlich G, Meier P, White S, Yellon D, Hausenloy D . Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013; 34(23):1714-22. DOI: 10.1093/eurheartj/eht090. View

17.

Boden W, ORourke R, Teo K, Hartigan P, Maron D, Kostuk W . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15):1503-16. DOI: 10.1056/NEJMoa070829. View

18.

Vuolteenaho O, Ala-Kopsala M, Ruskoaho H . BNP as a biomarker in heart disease. Adv Clin Chem. 2005; 40:1-36. View

19.

Kim M, Chung W, Cho Y, Choi S, Chae I, Choi D . Serum N-terminal pro-B-type natriuretic peptide levels at the time of hospital admission predict of microvascular obstructions after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Interv Cardiol. 2011; 24(1):34-41. DOI: 10.1111/j.1540-8183.2010.00606.x. View

20.

Jiang F, Sun L, Yang J . [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012; 31(12):1607-10. View